Pediatr. praxi. 2023;24(3):169-174 | DOI: 10.36290/ped.2023.050

Immunodysregulatory aspects of children with Down syndrome

MUDr. Peter Kunč, PhD.1, MUDr. Jaroslav Fábry, PhD.2, MUDr. Peter Ferenc, PhD.1, MUDr. Tomáš Strachan, PhD.1, MUDr. Michaela Matiščáková1
1 Národný ústav detskej tuberkulózy a respiračných chorôb, n. o., Dolný Smokovec
2 Klinika detskej tuberkulózy a respiračných chorôb JLF UK a Národného ústavu detskej tuberkulózy a respiračných chorôb, n. o., Dolný Smokovec

Unlike other rare genetic disorders, a paediatrician often encounters many cases of children with Down syndrome during clinical practice. This syndrome is characterised by the complexity of characteristic functional and structural manifestations in every organ system. The immune system of children with this syndrome is characterised by various functionally limiting disturbances related to the regulation of immune mechanisms that maintain the integrity of the organism against endogenous and exogenous factors. This results not only in an increased susceptibility to recurrent and severe respiratory infections, but also in a predisposition to selected autoimmune and oncological complications and inadequate pro-inflammatory responses to pathogens with a risk of developing sepsis with related poor outcomes. Acquiring important knowledge and consequent preventive, diagnostic and therapeutic interventions, the paediatrician can improve the health care provided to these children with an improved quality of life and reduction of limiting symptoms resulting from disturbances in balance and interactions between different parts of the immune system.

Keywords: children, Down syndrome, immune system, immunodysregulation, recurrent respiratory infections.

Accepted: June 8, 2023; Published: June 15, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kunč P, Fábry J, Ferenc P, Strachan T, Matiščáková M. Immunodysregulatory aspects of children with Down syndrome. Pediatr. praxi. 2023;24(3):169-174. doi: 10.36290/ped.2023.050.
Download citation

References

  1. Ni She R, Filan PM. Trisomy 21- incidence and outcomes in the first year, in Ireland today. Ir Med J. 2014;107(8):248-249. Go to PubMed...
  2. de Graaf G, Buckley F, Skotko BG. Estimation of the number of people with Down syndrome in Europe. Eur J Hum Genet EJHG. 2021;29(3):402-410. Go to original source... Go to PubMed...
  3. Ďurdíková V, Ďurdík P, Bánovčin P. Pridružené ochorenia u detí s Downovým syndrómom. Pediatr. 2008;3(6):338-342.
  4. Huggard D, Doherty DG, Molloy EJ. Immune Dysregulation in Children With Down Syndrome. Front Pediatr [Internet]. 2020;8. [cit. 2022-03-07] Available from: https://www.frontiersin.org/article/10.3389/fped.2020.00073. Go to original source... Go to PubMed...
  5. Lee YI, Peng CC, Chiu NC, et al. Risk factors associated with death in patients with severe respiratory syncytial virus infection. J Microbiol Immunol Infect. 2016;49(5):737-742. Go to original source... Go to PubMed...
  6. Garrison MM, Jeffries H, Christakis DA. Risk of Death for Children with Down Syndrome and Sepsis. J Pediatr. 2005;147(6):748-52. Go to original source... Go to PubMed...
  7. Kusters MA, Bok VLA, Bolz WEA, et al. Influenza A/H1N1 vaccination response is inadequate in down syndrome children when the latest cut-off values are used. Pediatr Infect Dis J. 2012;31(12):1284-1285. Go to original source... Go to PubMed...
  8. Illouz T, Biragyn A, Frenkel-Morgenstern M, et al. Specific Susceptibility to COVID-19 in Adults with Down Syndrome. Neuromolecular Med. 2021;23(4):561-571. Go to original source... Go to PubMed...
  9. Alsubie HS, Rosen D. The evaluation and management of respiratory disease in children with Down syndrome (DS). Paediatr Respir Rev. 2018;26:49-54. Go to original source... Go to PubMed...
  10. Ram G, Chinen J. Infections and immunodeficiency in Down syndrome. Clin Exp Immunol. 2011;164(1):9-16. Go to original source... Go to PubMed...
  11. Uhliarová B, Švec M. Dieťa s Downovým syndrómom v ambulancii ORL lekára. Pediatr. 2017;12(2):79-82.
  12. Eijsvoogel NB, Verstegen RHJ, van Well GTJ, et al. Increased rate of respiratory symptoms in children with Down syndrome: a 2-year web-based parent-reported prospective study. Eur J Pediatr. 2022;181(12):4079-4089. Go to original source... Go to PubMed...
  13. Weijerman ME, Brand PLP, van Furth MA, et al. Recurrent wheeze in children with Down syndrome: is it asthma? Acta Paediatr. 2011;100(11):e194-197. Go to original source... Go to PubMed...
  14. Perluigi M, Di Domenico F, Buttterfield DA. Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: Insights from proteomics. PROTEOMICS - Clin Appl. 2014;8(1-2):73-85. Go to original source... Go to PubMed...
  15. Huggard D, Kelly L, Ryan E, et al. Increased systemic inflammation in children with Down syndrome. Cytokine. 2020;127:154938. Go to original source... Go to PubMed...
  16. Pako J, Bikov A, Karlocai K, et al. Plasma VEGF levels and their relation to right ventricular function in pulmonary hypertension. Clin Exp Hypertens. 2015;37(4):340-344. Go to original source... Go to PubMed...
  17. Chotsampancharoen T, Chavananon S, Sripornsawan P, et al. Transient abnormal myelopoiesis in Down syndrome: Experience of long term follow up from a single tertiary center in Thailand. Pediatr Hematol Oncol. 2023;40(2):108-116. Go to original source... Go to PubMed...
  18. Schoch J, Rohrer TR, Kaestner M, et al. Quantitative, Phenotypical, and Functional Characterization of Cellular Immunity in Children and Adolescents With Down Syndrome. J Infect Dis. 2017;215(10):1619-1628. Go to original source... Go to PubMed...
  19. Marcovecchio GE, Bortolomai I, Ferrua F, et al. Thymic Epithelium Abnormalities in DiGeorge and Down Syndrome Patients Contribute to Dysregulation in T Cell Development. Front Immunol. 2019;10:447. Go to original source... Go to PubMed...
  20. Buc M. Heterogenita lymfocytov ako ústredných operačných jednotiek imunitného systému. Vnitř Lékařství. 2019;65(2):86-97. Go to original source...
  21. Rueda N, Flórez J, Martínez-Cué C. Apoptosis in Down's syndrome: lessons from studies of human and mouse models. Apoptosis Int J Program Cell Death. 2013;18(2):121-134. Go to original source... Go to PubMed...
  22. Huggard D, McGrane F, Lagan N, et al. Altered endotoxin responsiveness in healthy children with Down syndrome. BMC Immunol. 2018;19(1):31. Go to original source... Go to PubMed...
  23. Chung H, Green PHR, Wang TC, et al. Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence. J Inflamm Res. 2021;14:5187-5200. Go to original source... Go to PubMed...
  24. Khocht A, Russell B, Cannon JG, et al. Oxidative burst intensity of peripheral phagocytic cells and periodontitis in Down syndrome. J Periodontal Res. 2014;49(1):29-35. Go to original source... Go to PubMed...
  25. Bloemers BLP, van Bleek GM, Kimpen JLL, et al. Distinct abnormalities in the innate immune system of children with Down syndrome. J Pediatr. 2010;156(5):804-9, 809.e1-809.e5. Go to original source... Go to PubMed...
  26. Cossarizza A, Ortolani C, Forti E, et al. Age-related expansion of functionally inefficient cells with markers of natural killer activity in Down's syndrome. Blood. 1991;77(6):1263-1270. Go to original source...
  27. Satgé D, Seidel MG. The Pattern of Malignancies in Down Syndrome and Its Potential Context With the Immune System. Front Immunol. 2018;9:3058. Go to original source... Go to PubMed...
  28. Li YY, Alexandrov PN, Pogue AI, et al. miRNA-155 upregulation and complement factor H deficits in Down's syndrome. Neuroreport. 2012;23(3):168-173. Go to original source... Go to PubMed...
  29. Veteleanu A, Pape S, Davies K, et al. Complement dysregulation and Alzheimer's disease in Down syndrome. Alzheimer`s Dement J Alzheimer`s Assoc. 2022. https://doi.org/10.1002/alz.12799. Go to original source... Go to PubMed...
  30. Fitzgerald KA, Kagan JC. Toll-like Receptors and the Control of Immunity. Cell. 2020;180(6):1044-1066. Go to original source... Go to PubMed...
  31. Huggard D, Koay WJ, Kelly L, et al. Altered Toll-Like Receptor Signaling in Children with Down Syndrome. Mediators Inflamm. 2019;2019:4068734. Go to original source... Go to PubMed...
  32. Huggard D, Molloy EJ. Question 1: Palivizumab for all children with Down syndrome? Arch Dis Child. 2019;104(1):94-97. Go to original source... Go to PubMed...
  33. Gutfraind A, Galvani AP, Meyers LA. Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection. JAMA Pediatr. 2015;169(4): 341-348. Go to original source... Go to PubMed...
  34. Kimura T, Takeuchi M, Kawakami K. Utilization and efficacy of palivizumab for children with Down syndrome. Pediatr Int Off J Jpn Pediatr Soc. 2020;62(6):677-682. Go to original source... Go to PubMed...
  35. Huggard D, Molloy EJ. Question 1: Do children with Down syndrome benefit from extra vaccinations? Arch Dis Child. 2018;103(11):1085-1087. Go to original source... Go to PubMed...
  36. Espinosa JM. Down Syndrome and COVID-19: A Perfect Storm? Cell Rep Med. 2020;1(2):100019. Go to original source... Go to PubMed...
  37. Hüls A, Feany PT, Zisman SI, et al. COVID-19 Vaccination of Individuals with Down Syndrome - Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated. Vaccines. 2022;10(4):530. Go to original source... Go to PubMed...
  38. Cao C, Wang J, Li Y, et al. Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis. Int J Clin Pract. 2021;75(5):e13981. Go to original source... Go to PubMed...
  39. Marseglia GL, Benazzo M, Biasci P, et al. OM-85 in the prevention of respiratory infections: State-of-the-art and future perspectives in clinical practice. J Biol Regul Homeost Agents. 2021;35(3):847-863. Go to PubMed...
  40. Luan H, Zhang Q, Wang L, et al. OM85-BV Induced the Productions of IL-1β, IL-6, and TNF-α via TLR4- and TLR2-Mediated ERK1/2/NF-κB Pathway in RAW264.7 Cells. J Interferon Cytokine Res. 2014;34(7):526-536. Go to original source... Go to PubMed...
  41. Chia E, Clark A, Flynn B, et al. P549 Should children with down syndrome receive prophylactic antibiotics to prevent recurrent respiratory infections? Arch Dis Child. 2019; 104(Suppl 3):A373-A373. Go to original source...
  42. Huggard D, Kelly L, Worrall A, et al. Melatonin as an immunomodulator in children with Down syndrome. Pediatr Res. 2022;91(7):1812-1820. Go to original source... Go to PubMed...
  43. Saghazadeh A, Mahmoudi M, Dehghani Ashkezari A, et al. Systematic review and meta-analysis shows a specific micronutrient profile in people with Down Syndrome: Lower blood calcium, selenium and zinc, higher red blood cell copper and zinc, and higher salivary calcium and sodium. PloS One. 2017;12(4):e0175437. Go to original source... Go to PubMed...
  44. Stagi S, Lapi E, Romano S, et al. Determinants of Vitamin D Levels in Children and Adolescents with Down Syndrome. Int J Endocrinol. 2015;2015:896758. Go to original source... Go to PubMed...




Pediatrics for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.